Introduction and Purpose of the Session
The presenter introduces Category 3 sterile compounding under USP <797>, emphasizing that the presentation is intended to provide foundational understanding rather than a detailed implementation guide.
The session focuses on the systems and processes necessary to safely achieve extended Beyond-Use Dates (BUDs) while maintaining product quality and patient safety.
Understanding Category 3 Compounding
Category 3 compounding expands upon traditional Category 2 compounding by allowing longer Beyond-Use Dates when enhanced controls are implemented.
The presenter explains that Category 3 is not simply an extension of existing practices—it requires a significantly higher level of operational control, documentation, and quality management.
The Regulatory Landscape: Category 3 Between Traditional Compounding and Manufacturing
The webinar places Category 3 within the broader regulatory framework.
The presenter explains that Category 3 occupies the space between:
- Traditional 503A pharmacy compounding
- 503B outsourcing facilities
- Commercial pharmaceutical manufacturing
Category 3 is described as bridging an important gap by incorporating additional quality systems without becoming full-scale manufacturing.
Pillar One: Qualified Personnel
The first pillar emphasizes that personnel must be qualified, not simply competent.
This includes:
- Demonstrated knowledge and technical skills
- Ongoing education and competency assessment
- Consistent adherence to procedures
Personnel qualification forms the foundation of every successful Category 3 program.
Pillar Two: Environmental Monitoring
Environmental monitoring is presented as more than routine data collection.
The presenter stresses that monitoring should generate meaningful information that can be used to:
- Evaluate environmental control
- Detect trends
- Support quality decisions
- Verify continued process performance
A robust environmental monitoring program is essential for maintaining confidence in extended BUDs.
Pillar Three: Robust Stability Testing
The third pillar focuses on stability testing.
A comprehensive stability program supports:
- Scientific justification for extended Beyond-Use Dates
- Product quality over time
- Evidence-based decision making
The presenter highlights stability testing as one of the defining characteristics that differentiates Category 3 from traditional compounding.
Moving Beyond Compliance Toward “GMP-Light” Practices
A recurring theme is the concept of adopting "GMP-light" principles.
Rather than meeting only minimum USP requirements, facilities should strengthen:
- Documentation
- Quality systems
- Process control
- Continuous improvement
These enhancements help support the additional expectations associated with Category 3 compounding.
Achieving Extended Beyond-Use Dates (BUDs)
Extended BUDs are presented as the outcome of strong systems—not a regulatory entitlement.
Facilities must demonstrate:
- Qualified personnel
- Controlled environments
- Scientifically supported stability
- Reliable quality processes
Extended dating must be earned through evidence and consistency.
Best Practices for Implementing a Category 3 Program
The session concludes by emphasizing that successful implementation requires:
- Investment in quality systems
- Strong personnel training
- Robust environmental monitoring
- Stability testing programs
- A culture focused on continuous quality improvement
These elements work together to support safe, compliant Category 3 compounding.
Contec Healthcare
Compounding Pharmacy, Beyond-Use Dates (BUDs), Category 3 Compounding, Webinar
return to overview
back to top